Patents by Inventor Saad J. Kenderian

Saad J. Kenderian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210355190
    Abstract: This document provides methods and materials for generating T cells expressing a selected antigen receptor (e.g., a chimeric antigen receptor) in vivo. For example, viral particles containing nucleic acid encoding a selected antigen receptor, cells capable of producing such viral particles, and methods for administering such viral particles and/or cells to a mammal to generate T cells expressing that selected antigen receptor within the mammal are provided.
    Type: Application
    Filed: October 31, 2019
    Publication date: November 18, 2021
    Inventors: Saad J. Kenderian, Stephen James Russell
  • Publication number: 20210284714
    Abstract: This document provides methods and materials involved in treating cancer. For example, chimeric antigen receptor T cells having reduced levels of GM-CSF are provided. Also provided as methods for making and using chimeric antigen receptor T cells having reduced levels of GM-CSF.
    Type: Application
    Filed: March 22, 2021
    Publication date: September 16, 2021
    Applicants: HUMANIGEN, INC., MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Cameron DURRANT, Dale CHAPPELL, Saad J. KENDERIAN, Michelle J. COX, Reona SAKEMURA
  • Publication number: 20210246215
    Abstract: This invention provides chimeric antigen receptors (CARs) targeting human EphA3 and dual targeting CARs that bind to human EphA3 and to human mutant epidermal growth factor receptor variant III (EGFRvIII). This invention also relates to CAR-T cells comprising the provided CARs or the dual targeting CARs. Methods for treating a solid tumor cancer by administering the CARs are provided.
    Type: Application
    Filed: November 9, 2020
    Publication date: August 12, 2021
    Applicants: HUMANIGEN, INC., MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Cameron DURRANT, Dale CHAPPELL, Saad J. KENDERIAN
  • Publication number: 20210214723
    Abstract: This document provides methods and materials involved in treating cancer. For example, chimeric antigen receptor T cells having reduced levels of GM-CSF are provided. Also provided as methods for making and using chimeric antigen receptor T cells having reduced levels of GM-CSF.
    Type: Application
    Filed: May 31, 2019
    Publication date: July 15, 2021
    Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Saad J. KENDERIAN, Rosalie M. STERNER, Michelle J. COX, Reona SAKEMURA
  • Publication number: 20210145881
    Abstract: This document provides methods and materials involved in treating a mammal (e.g., a human) having (or risk of developing) graft-versus-host disease (GVHD). For example, T cells (e.g., regulatory T cells) expressing one or more antigen receptors targeting one or more epithelial-specific antigens are provided. Also provided are methods for administering T-cells expressing one or more antigen receptors targeting one or more epithelial-specific antigens to a mammal having (or at risk of developing) GVHD to treat the GVHD.
    Type: Application
    Filed: April 9, 2019
    Publication date: May 20, 2021
    Inventors: Saad J. Kenderian, Mehrdad Hefazi Torghabeh
  • Publication number: 20210145830
    Abstract: This document provides methods for determining biological age of mammalian subjects or assessing whether the subjects are aging normally. Also provided herein are methods for determining whether therapeutic treatment or other interventions for reversing or slowing down aging are effective. This document also provides methods and materials for slowing the progression of biological aging.
    Type: Application
    Filed: April 5, 2019
    Publication date: May 20, 2021
    Inventors: Saad J. Kenderian, Neil E. Kay, Reona Sakemura, Steven L. Warner, David J. Bearss, Jason Marc Foulks, Lars Mouritsen, Clifford J. Whatcott